Rockefeller Capital Management’s Galectin Therapeutics GALT Stock Holding History

Rockefeller Capital Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.4K	Hold	4,386	–	–	﹤0.01%	3729
2026 Q1	$12.2K	Hold	4,386	–	–	﹤0.01%	3908
2025 Q4	$18.2K	Hold	4,386	–	–	﹤0.01%	3552
2025 Q3	$18.6K	Buy	+4,386	New	+$16.5K	﹤0.01%	3381
2023 Q1	–	Sell	-8,886	Closed	-$10K	–	2710
2022 Q4	$10K	Hold	8,886	–	–	﹤0.01%	3073
2022 Q3	$14K	Hold	8,886	–	–	﹤0.01%	2929
2022 Q2	$11K	Hold	8,886	–	–	﹤0.01%	3063
2022 Q1	$14K	Sell	8,886 -4,000	-31%	-$7.74K	﹤0.01%	2885
2021 Q4	$26K	Hold	12,886	–	–	﹤0.01%	2513
2021 Q3	$49K	Buy	12,886 +2,500	+24%	+$8.47K	﹤0.01%	2148
2021 Q2	$33K	Buy	10,386 +8,386	+419%	+$29.8K	﹤0.01%	2257
2021 Q1	$4K	Hold	2,000	–	–	﹤0.01%	2962
2020 Q4	$4K	Hold	2,000	–	–	﹤0.01%	2488
2020 Q3	$5K	Hold	2,000	–	–	﹤0.01%	2218
2020 Q2	$6K	Hold	2,000	–	–	﹤0.01%	2030
2020 Q1	$4K	Hold	2,000	–	–	﹤0.01%	2012
2019 Q4	$6K	Buy	+2,000	New	+$6.95K	﹤0.01%	1740

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rockefeller Capital Management's GALT Position: Q2 2026 in Review

Rockefeller Capital Management held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 4,386 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3729.

Rockefeller Capital Management first reported a position in GALT in Q4 2019 and has held it in 17 quarters since. The position peaked at $49K in Q3 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Rockefeller Capital Management held 4,386 shares of Galectin Therapeutics worth $20.4K as of Q2 2026.
Rockefeller Capital Management left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3729 holding.
Rockefeller Capital Management first reported a position in Galectin Therapeutics in Q4 2019 and has held it in 17 quarters since.
Rockefeller Capital Management's Galectin Therapeutics position peaked at $49K in Q3 2021.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.